Data Foundry

Drug recalls 2022

Bupivacaine Hydrochloride — Class II drug recall D-1095-2022

Terminated recall by Mckesson Medical-Surgical Inc. Corporate Office, reported 2022-06-15, distributed nationwide. cGMP deviations: Temperature abuse

Recall numberD-1095-2022
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmMckesson Medical-Surgical Inc. Corporate Office, Richmond, VA, United States
Recall initiated2022-04-13
Classified2022-06-09
Reported by FDA2022-06-15
Terminated2023-11-30
DistributedNationwide (US)
Quantity30 vials
Reason classescgmp, temperature control
NDC00409-1159, 00409-1159-01, 00409-1159-02, 00409-1159-18, 00409-1159-19, 00409-1160, 00409-1160-01, 00409-1160-18, 00409-1162, 00409-1162-01, 00409-1162-02, 00409-1162-18, 00409-1162-19, 00409-1163, 00409-1163-01, 00409-1163-18, 00409-1165, 00409-1165-01, 00409-1165-02, 00409-1165-18, 00409-1165-19, 00409-9042, 00409-9042-01, 00409-9042-11, 00409-9042-16 and 12 more

Product

Bupivacaine Hydrochloride, USP 0.5% (5mg/mL), 25 vials x 50 mL per box, Rx only, MFG: Pfizer, NDC 0409-1163-01

Reason for recall

cGMP deviations: Temperature abuse

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1095-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.